

include, but are not limited to, the collection of data on the number of participants served, referral sources,

kinds of services delivered, project goals, and other relevant data.
Respondents: State Access and Visitation Program Coordinators and

administrators of state and/or local service providers.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
Grants to States: Access and Visitation Program Survey (1 additional year.—to collect FY 2001 program data in FY 2003).	324	1	15	4,860
State Child Access Program Survey (FY 2003, 2004, 2005).	324	1	15	4,860
Estimated Total Annual Burden Hours:	Average 6,480 over 3 yrs. (9,720 in FY 2003; 4,860 in FY 2004; 4,860 in FY 2005.

Additional Information: Copies of the proposed collection may be obtained by writing to the Administration for Children and Families, Office of Administration, Office of Information Services, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer.

OMB Comment: OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, 725 17th Street, NW., Washington, DC 20503, Attn: Desk Officer for ACF.

Dated: January 21, 2003.

Robert Sargis,

Reports Clearance Officer.

[FR Doc. 03-1971 Filed 1-28-03; 8:45 am]

BILLING CODE 4184-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Minimally Immunogenic Variant of Humanized COL-1 Antibody Against Carcinoembryonic Antigen (CEA)

Syed V.S. Kashmiri (NCI), Jeffrey Schlom (NCI), Eduardo A. Padlan (NIDDK)

DHHS Reference No. E-239-2002/0-US-01 filed 05 Sep 2002

Licensing Contact: Jonathan Dixon; 301/435-5559; dixonj@od.nih.gov

Monoclonal antibodies (mAbs) show promise for the diagnosis and treatment of human cancers. COL-1 has a high affinity for carcinoembryonic antigen (CEA), and it reacts specifically to CEA. The present invention discloses humanized COL-1 (HuCOL-1) mAbs that are potentially minimally immunogenic and retain CEA binding affinity. Humanization of the antibody by "abbreviated" CDR grafting has reduced the risk of human anti-murine antibody response associated with the clinical use of murine mAbs for

diagnosis and treatment of CEA expressing tumors. This invention also provides further methods of detecting and treating CEA expressing tumors.

Novel Broadly Cross-Reactive HIV Neutralizing Human Monoclonal Antibodies Selected From Fab Phage Display Libraries Using a Novel Strategy Based on Alternative Antigen Panning

Dimitar S. Dimitrov (NCI) and Mei-Yun Zhang (SAIC)

DHHS Reference No. E-144-2002/0-US-01 filed 05 May 2002 and

Novel Broadly Cross-Reactive HIV-1 Neutralizing Human Single-Chain Antibodies Derived From X5 by DNA Shuffling and Alternating Antigen Panning

Dimitar S. Dimitrov (NCI) and Mei-Yun Zhang (SAIC)

DHHS Reference No. E-144-2002/1-US-01 filed 05 May 2002

Licensing Contact: Sally Hu; 301/435-5606; hus@od.nih.gov

This invention (E-144-2002/0-US-01) identifies four antibodies, designed m12, m14, m16, and m18. These four antibodies were isolated from a human Fab phage display library using alternating antigen panning (AAP). All four antibodies bind to recombinant HIV envelope glycoproteins (Env)_{gp12089.6}, gp120JR-FL and gp120HIB with high affinity. Moreover, m12 binding to gp120 or gp140 is significantly enhanced in the presence of the receptor CD4. The second invention (E-144-2002/1-US-01) describes two scFv clones, designated M6 and M9 that were selected from phage-displayed X5 scFv mutants library by panning the library against gp12089.6/HIB-CD4 complex using